Masimo's Wearable Thermometer Scores FDA Approval For Prescription, OTC Use

by Vandana Singh, Benzinga Editor

June 21, 2021 11:23 AM | 1 min read |

Masimo MASI has announced that Radius Tº, a wearable, wireless thermometer, has received FDA 510(k) clearance for both prescription and over-the-counter (OTC) use on patients and consumers five years and older.
With continuous temperature measurements and Bluetooth connectivity, Radius Tº automates remote, ongoing body temperature status for clinicians through its paired connection to a Masimo patient monitoring or telehealth solution and for consumers through the Masimo Radius Tº smartphone application.
For prescription use, Radius Tº is compatible with both the Root Patient Monitoring and Connectivity Hub and the Rad-97 patient monitor for use in the hospital, as part of the Masimo Hospital Automation platform.
Price Action: MASI shares are down 1.27% at $237 during the market session on the last check Monday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.